6 December 2016Americas

Actavis hit with IP suit over prostate cancer drug

Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi (enzalutamide), a treatment for prostate cancer.

The suit, which was filed on Friday, December 2 in the US District Court for the District of Delaware, involves US patent numbers 7,709,517; 8,183,274; and 9,126,941.

The dispute arose after Actavis filed an Abbreviated New Drug Application (ANDA) with the Food and Drug Administration seeking approval to market a generic version of Xtandi before the expiration of the patents involved.

Xtandi is sold and co-promoted by Astellas Pharma and Medivation in the US, where they have been granted an exclusive licence by the regents, which owns the patents.

The suing companies have asked the district court for a judgment that says claims of the three patents have been infringed by Actavis by submitting the ANDA.

They are further seeking a permanent injunction restraining Actavis from bringing a generic product of Xtandi to market, as well an award of costs.


More on this story

Big Pharma
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.

More on this story

Big Pharma
23 March 2023   NIH rejects petition to use “march-in” rights to allow cheaper competition | Xtandi is “widely available” to public, federal agency says.